Rationale Many addictive drugs are known to have effects on learning and memory, and these effects could motivate future drug use. Specifically, addictive drugs may affect memory of emotional events and experiences in ways that are attractive to some users. However, few studies have investigated the effects of addictive drugs on emotional memory in humans. Objectives This study examined the effects of the memoryenhancing drug dextroamphetamine (AMP) and the memory-impairing drug Δ 9 -tetrahydrocannabinol (THC) on emotional memory in healthy volunteers. Methods Participants completed three experimental sessions across which they received capsules containing placebo and two doses of either AMP (10 and 20 mg; N025) or THC (7.5 and 15 mg; N025) before viewing pictures of positive (pleasant), neutral, and negative (unpleasant) scenes. Memory for the pictures was assessed 2 days later, under drug-free conditions. Results Relative to placebo, memory for emotional pictures was improved by AMP and impaired by THC, but neither drug significantly affected memory for unemotional pictures. Positive memory biases were not observed with either drug, and there was no indication that the drugs' memory effects were directly related to their subjective or physiological effects alone. Conclusions This study provides the first clear evidence that stimulant drugs can preferentially strengthen, and cannabinoids can preferentially impair, memory for emotional events in humans. Although addictive drugs do not appear to positively bias memory, the possibility remains that these drugs' effects on emotional memory could influence drug use among certain individuals.
Introduction
Memories of emotional events exert a strong influence over behavior. Certainly it is often advantageous for survival to remember emotional events, as these memories can motivate harm avoidance and pursuit of biologically relevant rewards (e.g., food and sex) (Nairne et al. 2007 ). However, memories of emotional events can also have pernicious consequences. For instance, posttraumatic stress disorder is associated with invasive memories of traumatic events (Steckler and Risbrough 2012) and clinically depressed patients often more readily remember negative events than positive ones (Leppanen 2006) . Overactive memories of positive events can also be detrimental, as they may lead to compulsive behavior. Indeed drug addiction is increasingly viewed as a disorder of learning and memory, and recent theories posit potent memories of previous positive drug experiences promote compulsive drug use (Hyman 2005; Koob 2009; Robbins et al. 2008) . But while anecdotal reports from drug users provide some support for this view, there are also reports of people using drugs to cope with, or 'to forget', painful life events (Bell 1996; Boys et al. 2001; Crowley 1972; Pandina and Johnson 1999) , suggesting that addictive drugs may influence how emotional events are remembered in ways that are attractive to certain individuals. Nevertheless, only a handful of controlled laboratory studies have investigated the effects of addictive drugs on emotional memory in humans.
In the present study, we examined the effects of two different addictive drugs-dextroamphetamine (AMP) and Δ 9 -tetrahydrocannabinol (THC)-on emotional memory in healthy human volunteers. We chose to study these two drugs in part because both are widely used for their euphorigenic properties, but have distinctly different behavioral, pharmacological, and cognitive effects. AMP is a prototypic stimulant drug that acts directly at vesicular monoamine transporters to increase synaptic concentrations of monoamines (primarily dopamine (DA) and norepinephrine (NE)) (Patrick and Markowitz 1997; Rothman et al. 2001) . THC, on the other hand, has more sedative effects (Robson 2001) , and acts as a partial agonist at cannabinoid receptors (Howlett et al. 2004; Tanda and Goldberg 2003) . At moderate doses, AMP can enhance memory encoding by increasing alertness (Estrada et al. 2012) , vigilance (Killgore et al. 2008) , focused attention (Hamidovic et al. 2010) , and motivation (Wardle et al. 2011) , and by enhancing working memory (Tipper et al. 2005) , associative learning (Breitenstein et al. 2006) , and cognitive flexibility (Kempton et al. 1999) , while THC adversely impacts many of these same processes (for a review, see Ranganathan and D'Souza 2006) . Accordingly, several studies have shown people exhibit superior memory for lists of unemotional words studied under the influence of AMP (e.g., Breitenstein et al. 2004; Mintzer and Griffiths 2003; Zeeuws and Soetens 2007) , whereas THC generally impairs memory under similar conditions (for a review, see Ranganathan and D'Souza 2006) . AMP similarly improves memory when it is administered immediately after encoding (list studying) (Soetens et al. 1993) , indicating it also enhances consolidation of recently encoded memories. Although clear evidence that THC impairs memory consolidation in humans has not been shown, cannabinoid agonists typically impair memory retention in rodents when administered immediately after training (Campolongo et al. 2009; Clarke et al. 2008; Costanzi et al. 2004; Ghiasvand et al. 2011 ). To our knowledge, neither AMP nor THC has previously been evaluated on measures of long-term declarative emotional memory in humans.
We hypothesized that AMP would preferentially enhance, and THC would preferentially impair, memory for emotional stimuli relative to neutral stimuli. This prediction was based primarily on functional neuroimaging studies showing that AMP potentiates , while THC dampens (Bhattacharyya et al. 2010; Phan et al. 2008) , amygdalar activation in response to emotional images in humans. The amygdala is highly sensitive to emotionally arousing stimuli (both positively and negatively valenced), and its activation may serve to strengthen memory consolidation (for a review, see Roozendaal and McGaugh 2011) . Moreover, experimental procedures that increase amygdalar reactivity to emotional images (e.g., stress (van Marle et al. 2009 ) and cortisol (Henckens et al. 2012) ) preferentially enhance memory for emotional stimuli when administered prior to encoding in humans (Buchanan and Lovallo 2001; Payne et al. 2007 ). Evidence of selective emotional memory impairments in humans also has been observed with preencoding administration of several drugs that dampen amygdalar reactivity to emotional images, including both addictive drugs (e.g., alcohol (Gilman et al. 2008; Knowles and Duka 2004) , benzodiazepines (Buchanan et al. 2003; Del-Ben et al. 2010; Kamboj and Curran 2006; Paulus et al. 2005) ) and non-addictive drugs (e.g., dopaminergic receptor antagonists (Gibbs et al. 2007; Mehta et al. 2005; Takahashi et al. 2005) , β-adrenergic receptor antagonists (Cahill et al. 1994; van Stegeren et al. 1998; van Stegeren et al. 2005) )-findings which additionally provide mechanistic support for our hypothesis. This hypothesis also appears to be consistent with research indicating that emotional memory consolidation varies directly with arousal state. In line with this view, both stress and cortisol similarly enhance emotional memory when administered immediately after encoding (Kuhlmann and Wolf 2006; Smeets et al. 2008) , and an analogous effect has been observed following the viewing of either pleasant or aversive arousing videos (Liu et al. 2008) . On the other hand, listening to relaxing music during or immediately after encoding correspondingly preferentially impairs emotional memory in humans (Liu et al. 2008) .
Our predictions regarding the emotional memory effects of AMP and THC in humans are also broadly congruent with the nonhuman animal literature. In particular in rodents, AMP typically enhances (Davies et al. 1974; Fulginiti and Cancela 1983; Janak and Martinez 1992; Lee and Ma 1995; Martinez et al. 1980; Wood and Anagnostaras 2009) , whereas cannabinoid agonists typically impair (for reviews, see Akirav 2011; McLaughlin and Gobbi 2012) acquisition and retention of motivated conditioned behaviors. Still, direct comparisons of emotional and unemotional memory in non-human animals are lacking, which limits the conclusions that can be drawn regarding the importance of emotional task elements in mediating the effects of drugs on performance in preclinical models. The present study therefore builds on prior research concerning the factors that modulate emotional memory in humans, and it addresses gaps in the preclinical literature.
We separately hypothesized that AMP might preferentially enhance memory for positive relative to negative stimuli, while THC might preferentially impair memory for negative relative to positive stimuli. This prediction was based primarily on the drugs' capacity to induce positive mood states, as a sizeable literature indicates that information is more likely to be remembered if its valence matches the individual's mood state during encoding (for reviews, see Bower and Forgas 2000; Eich 2001) . Along these lines, it stands to reason that addictive drugs may positively bias memory of the events surrounding drug use, resulting in users preferentially remembering subjectively positive aspects of the drug use experience over more negative ones. Such a positive memory bias would fit broadly with the above-noted anecdotal reports from drug users of the factors that motivate drug use, and there is evidence that drug users' memory of subjectively positive drug effects overshadows their memory of negative drug effects (McCusker 2001) . Nevertheless, the possibility that addictive drugs may differentially modulate memory for positively and negatively valenced emotional stimuli has rarely been explored in controlled laboratory studies.
We are aware of only two studies that have measured effects of addictive drugs on long-term declarative memory for both positive and negative emotional stimuli in humans. Those studies found little evidence that either alcohol (Knowles and Duka 2004) or the benzodiazepine triazolam (Buchanan et al. 2003 ) impaired memory more strongly for negative relative to positive images. Nevertheless, evidence that acute treatment with NE reuptake inhibitors prior to encoding preferentially increases delayed (15 min) recall of positive self-relevant adjectives in healthy humans in the absence of measurable acute changes in mood state (for a review, see Harmer et al. 2011) provides mechanistic support for an AMP-induced positive memory bias. As well, evidence that acute treatment with a cannabinoid inverse agonist prior to encoding preferentially increases delayed (15 min) recall of negative self-relevant adjectives in healthy humans without altering mood state (Horder et al. 2009 ) provides indirect mechanistic support for a THC-induced positive memory bias. Thus, even though clear evidence that addictive drugs positively bias memory is currently lacking, it remains possible that positive memory biases might be detected with AMP and THC.
Our primary interest in this study was to investigate how AMP and THC affect long-term memory for emotional events encountered under the influence. Drugs were administered before participants viewed a range of emotionally positive, neutral, and negative pictures, and memory was tested under drug-free conditions 2 days later. As such, the drugs could potentially directly affect both memory encoding processes and early consolidation, but retrieval was assessed in the absence of any drug effects. Participants ingested placebo capsules and two different doses of either AMP (10, 20 mg) or THC (7.5, 15 mg) across separate sessions in counterbalanced order under double-blind conditions. Drug doses are within the range shown to affect memory for unemotional information when administered prior to encoding in humans (e.g., Ballard et al. 2012b; Curran et al. 2002; Mintzer and Griffiths 2003; Zeeuws and Soetens 2007) . Measures of subjective drug response, mood state, and cardiovascular function were obtained and examined in relation to the drugs' memory effects.
Methods

Subjects
Healthy volunteers aged 18-35 years were recruited from the University of Chicago and the surrounding community via posters, advertisements, and word-of-mouth referrals, and participated either in the AMP study (N 025; 12 females) or the THC study (N025; 11 females). The studies were conducted separately but utilized the same inclusion criteria and procedure. All potential participants underwent a physician-supervised physical examination including an electrocardiogram, completed a health questionnaire with detailed information on current and lifetime drug use, and were interviewed by trained clinical psychologists using a semi-structured SCID interview. Exclusion criteria included current Axis I DSM-IV disorder including any Substance Dependence other than Tobacco Dependence (American Psychiatric Association [DSM-IV-TR], 2003) other than tobacco dependence. Tobacco dependence does not appear to affect subjective response to the drugs used in this study (unpublished, in-house analyses, N0400 for AMP, N030 for THC). Volunteers were excluded if they had a history of psychosis or mania, less than a high school education, lack of fluency in English, a body mass index outside of 19-26 kg/m 2 , high blood pressure (>140/90), an abnormal electrocardiogram, reported daily use of any medication other than birth control, or were pregnant, lactating, or planning to become pregnant in the next 3 months. For ethical reasons, participants were only eligible if they reported using cannabis more than ten times in their lifetime with no serious cannabis-related adverse events. Inclusion was limited to individuals not currently using cannabis more than three times per week, to reduce the likelihood of tolerance to THC's effects on memory (D'Souza et al. 2008) . Women not taking hormonal contraceptives in the AMP group (n06 of 12) were tested during their follicular phase only because hormonal fluctuations of the menstrual cycle can influence responses to the drug (White et al. 2002) .
Design
Two parallel studies were carried out investigating the respective effects of AMP and THC on emotional memory encoding. Both studies utilized a three-session, doubleblind, placebo-controlled, counterbalanced, cross-over design. Each of the three sessions consisted of two laboratory visits-a 4-h visit (encoding phase) followed 2 days later by a 1-h visit (retrieval phase). During the encoding phase visits, participants received capsules containing placebo or AMP (10 and 20 mg; AMP group) or THC (7.5 and 15 mg; THC group) in random order, before viewing standardized pictures (see "Dependent measures," below). Memory for the pictures viewed during the encoding phase visit was assessed at the subsequent retrieval phase visit, during which no drugs were administered. Additional procedures were included to assess the drugs' effects on processing of facial emotions and on associative false memory, but they will not be described here. These additional procedures were held constant with respect to the current procedure and have been reported previously (Ballard et al. 2012a; Ballard et al. 2012b ). This study was approved by the University of Chicago Institutional Review Board.
Procedure
Qualifying participants attended a 1-h orientation session to be acquainted with the study procedures and risks, provide informed consent, and practice study tasks and questionnaires. They were informed that they would be participating in a study on the effects of drugs on mood and memory. To minimize drug-related expectancies, all participants were told that they might receive a placebo, stimulant (e.g., amphetamine), sedative/tranquilizer (e.g., valium), or a marijuanalike drug. Participants were instructed to consume their normal amounts of caffeine and nicotine before sessions, but to abstain from using alcohol and prescription (other than birth control), over the counter, and illicit drugs for 24 h before the sessions. They were notified that they would be tested for drug use before each session to verify abstinence. Participants were also advised to get their normal amounts of sleep, and not to eat solid food for 2 h before the encoding phase visits to allow for proper drug absorption.
Participants were tested individually in comfortably furnished rooms with a television and VCR, magazines, and a computer for administering questionnaires and tasks. They were allowed to watch television, selected neutral movies, or read when no measures were being obtained, but they were not allowed to sleep, work, or study, and they had no access to cell phones or internet. Upon arrival for all six visits, participants first completed compliance measures including breath alcohol level (Alco-sensor III, Intoximeters, St. Louis, MO) and urine drug (ToxCup, Branan Medical Co. Irvine, CA) and pregnancy (women only, using an hCG assay; Aimstrip, Craig Medical, Vista, CA) tests. During the encoding phase visits, after completing pre-capsule subjective ratings and physiological measures (see "Dependent measures," below), participants ingested capsules (0 min) containing placebo or active drug with 100 mL water. Every 30 min for the remainder of the encoding phase visits, participants completed subjective mood and drug effect ratings, and provided cardiovascular measurements. At 90 min after capsule ingestion, when peak drug effects were expected to be present (Wachtel et al. 2002; White et al. 2007 ), participants viewed the pictures for which their memory would be tested 2 days later. At the end of the encoding phase visits, participants completed an end-of-session questionnaire, and were allowed to leave when residual subjective and physiological drug effects had subsided. During the retrieval phase visits, participants returned to the laboratory for 1 h to complete mood questionnaires and the recognition memory task. All participants were fully debriefed at study completion.
Dependent measures
Memory task
Memory was measured using a common picture recognition procedure, which was designed to assess participants' ability to discriminate previously studied pictures from novel distractor pictures. The stimuli consisted of six sets of 60 pictures drawn from the International Affective Picture System (IAPS; Lang et al. 1999) . Each set was comprised of photographs depicting a range of positive or pleasant, neutral, and negative or unpleasant scenes (20 each category), according to normative ratings, and all six picture sets were matched on extremity of valence and arousal. Normed valence ratings of IAPS pictures range from 1 (very negative) to 9 (very positive), and arousal ratings range from 1 (not at all arousing) to 9 (very arousing). Positive pictures selected for this study had a mean valence of 7.05 (range, 6-8.34) and mean arousal of 5.58 (range, 4.51-7.35); neutral pictures had a mean valence of 5.07 (range, 4.03-5.99) and a mean arousal of 3.35 (range, 1.72-4.36); Negative pictures had a mean valence of 2.73 (range, 1.46-3.92) and a mean arousal of 5.6 (range, 4.53-7.29) (Lang et al. 1999) . Participants viewed a different picture set during each of the encoding phase visits after receiving active drug or placebo. Their memory for the pictures was then tested 2 days later, at the corresponding retrieval phase visit. There, participants performed a recognition test during which they were instructed to correctly identify the previously viewed pictures from a set containing an equal number of novel (unstudied) distractor pictures. The same two sets of pictures were always paired together during a single test. Set order was counterbalanced across participants, and sets were not re-used across sessions. IAPS pictures reliably elicit emotional responses and are commonly used as a tool for examining emotional memory in humans.
Encoding phase During each of the three encoding phase visits, participants viewed a single set of 60 pictures. Pictures were displayed individually on a computer screen for 3,000 ms each and were pseudorandomized such that no more than two pictures from the same valence category were presented consecutively. The participant initiated the presentation of each picture by pressing a key. To ensure that the studied pictures would meaningfully processed under each of the drug conditions, participants were required to rate each picture for perceived valence and arousal, using Likert scales from one to nine. Valence was defined as: (1) how positive and (2) how negative the pictures made them feel, and arousal was defined as how stimulated, excited, or awake they felt in response to the picture (Lang et al. 1993) . Valence and arousal ratings were self-paced. Outcome measures included subjective ratings of positivity, negativity, and arousal response to pictures from individual valence categories.
Retrieval phase Two days after each encoding phase visit, participants returned to the laboratory for a retrieval phase visit, to test their memory for the pictures viewed during the previous encoding phase visit. At each retrieval phase visit, memory was assessed using all 60 of the pictures from the set studied at the previous encoding phase visit, interspersed with 60 novel pictures, presented in the same manner as during the encoding phase. Participants were instructed to identify pictures they had seen 2 days earlier during the encoding phase visit (yes/no), and to rate their current positivity, negativity, and arousal responses to each. Raw outcome measures included hit rate (the proportion of studied pictures correctly recognized as studied at test), false alarm rate (the proportion of unstudied pictures incorrectly recognized as studied at test), and valence and arousal ratings. The main outcome measure was a calculated score of memory accuracy derived from subtracting false alarm rate from hit rate. This method of subtracting false alarms from hits is widely used in order to control for changes in base rate responding (Snodgrass and Corwin 1988) .
Subjective effects measures
Participants completed several subjective mood and drug effect rating scales as described previously (Ballard et al. 2012a) . Briefly, these included the Drug Effects Questionnaire (DEQ; Fischman and Foltin 1991), Visual Analog Scales (VAS; Folstein and Luria 1973) , and Positive Affect and Negative Affect Schedule (PANAS; Watson et al. 1988) , which were administered at baseline and every 30 min after capsule ingestion, the Addiction Research Center Inventory (ARCI; Martin et al. 1971) , which was administered at baseline and 90 and 180 min post-capsule, and an end-of-session questionnaire administered at 180 min post-capsule. The DEQ includes five questions that measure how much participants feel a drug effect, dislike the drug effect, like the drug effect, feel high, and want more of the drug. The VAS includes the adjectives "anxious," "stimulated," "confused," "sedated," "excited," "angry," and "elated." The PANAS consists of ten negative and ten positive mood terms designed to measure positive and negative effects. The ARCI measures drug-specific effects on a true-false questionnaire. The ESQ measures overall perception of drug effects, including: (1) desire to take the drug again "yes/no" and (2) best guess of drug received (stimulant, sedative/anxiolytic, marijuana-like drug, or placebo).
For the purpose of this study, we focused on four ratings: subjective stimulation and sedation (VAS scales; range, 0 to 10), a composite measure of drug preference (calculated as DEQ ratings of "like drug" minus DEQ ratings of "dislike drug"; range, −10 to +10), and overall drug effect (DEQ ratings of "feel drug" (range, 0 to 10). We calculated mean change from pre-capsule baseline scores acquired immediately before and after encoding phase picture set viewing (+90 and +120 min post-capsule) to estimate drug effects at the time the pictures were viewed. Subjective stimulation and sedation were selected because changes in arousal may preferentially influence memory for emotionally salient stimuli, and drug preference was selected because positive and negative subjective drug responses may correspond to positive and negative memory biases, respectively. Drug "feel" was selected to investigate the importance of overall awareness of drug effects to their memory effects.
Physiological effects measures
Blood pressure and heart rate were measured at baseline, and every 30 min post-capsule, using a portable digital blood pressure monitor (AND Medical/Life Source, San Jose, CA). Mean change from pre-capsule baseline scores acquired immediately before and after encoding phase picture set viewing (+90 and +120 min post-capsule) were calculated and examined in relation to effects of the study drugs on memory. These measures were selected because, like subjective stimulation, physiological arousal changes may similarly accompany preferential emotional memory changes. Drugs AMP (Barr Laboratories, Pomona, New York) and THC (Marinol® [dronabinol] ; Solvay Pharmaceuticals, Marietta, Georgia) were placed in opaque size 00 capsules in doses of 10 or 20 mg (AMP) or 7.5 or 15 mg (THC), with dextrose filler. Placebo capsules contained only dextrose. Capsules were administered in counterbalanced order under double-blind conditions. These doses of AMP and THC are within the range shown to affect memory in previous studies (e.g., Ballard et al. 2012b; Curran et al. 2002; Mintzer and Griffiths 2003; Zeeuws and Soetens 2007) , and the oral route ensures a steady time course of response throughout the study session (Wachtel et al. 2002; White et al. 2002 ).
Statistical analyses
Memory task
Memory task data were analyzed to determine the drugs' overall effects on emotional evaluation and memory accuracy using two-way repeated-measures ANOVA with drug dose (placebo, low, and moderate) and picture valence (positive, neutral, and negative) as the within-subjects factors. Furthermore, in order to fully explore our two noncompeting hypotheses that the drugs would more strongly affect memory for pictures of certain valence, we also examined the size of the effect each drug had on responses to items from each valence category using individual one-way repeated-measures ANOVA. Because we expected dosedependent increases in drug effects, linear main effects of drug dose are reported, unless otherwise specified (i.e., when the lower dose was found to exert a stronger effect than the higher dose). Quadratic valence effects are reported because we were interested in investigating the extent to which each drug affected emotional pictures (both positiveand negative valence) more strongly than unemotional pictures (neutral valence). Alpha was set at p00.05 for all analyses, and trend-level main effects of drug dose (p< 0.1) were followed up by post hoc paired t tests, to examine dose dependency. One-tailed tests were used because we had specific predictions about the direction of the drugs' effects on memory (i.e., that AMP would enhance, whereas THC would impair, memory performance relative to placebo). All data reported related to the memory task (i.e., both picture ratings and memory performance) reflect an n024 in both groups. One participant in the AMP group received the wrong picture set during one of the encoding visits, and one participant in the THC group did not adhere to the memory task instructions during the high dose condition, and these participants were therefore excluded from these analyses.
Emotional processing data Participants' subjective ratings of their positive, negative, and arousal responses to the pictures were analyzed for: (1) the studied pictures at encoding, (2) the studied pictures at retrieval, and (3) the distractor pictures at retrieval. These analyses were chosen to provide information on the drugs' effects on perception, which may influence memory. Neither drug influenced the ratings at retrieval when administered on the study day, so these results are not discussed.
Memory data Memory accuracy, hit rate, and false alarm rate data were first analyzed using pre-determined valence categories according to normed ratings but were also reanalyzed using individualized valence and arousal categories according to each individual participant's valence and arousal ratings of the pictures. For the subjective rating analyses, pictures were sorted in descending order of subjective positivity minus negativity into three valence categories (positive, neutral, and negative). Reanalysis of each participant's memory data according to valence categories determined by their own subjective ratings of picture valence yielded analogous results to those obtained using normatively determined valence categories. Thus, only analyses of the former are provided for ease of interpretation with respect to effects of the drugs on subjective picture ratings.
Subjective and physiologic effects of AMP and THC at encoding and relation to memory performance Drug effects on subjective and physiologic state were analyzed using one-way repeated-measures ANOVA, with drug dose (placebo, lower, and higher) as the within-subject factor. Significant main effects of drug dose were followed by paired t tests. We also performed exploratory analyses to examine relationships between the drugs' effects on memory and their effects on subjective and physiologic state. Bivariate correlational analyses of drug effect (drug minus placebo) were conducted on these measures for each dose of each drug separately. We looked for relationships between memory performance (memory accuracy, hit rate, and false alarm rate for positive and negative vs. neutral pictures separately) and the drugs' effects on subjective measures (drug preference, "feel drug," "stimulated," and "sedated") and cardiovascular measures (systolic and diastolic blood pressure and heart rate). Alpha was set liberally at p00.05 for correlational analyses, given the exploratory nature of these analyses and to facilitate generation of novel hypotheses for future investigation.
Results
Participant characteristics
Demographic characteristics and past-month drug use of the participants in the AMP (N025; 12 females) and THC (N025; 11 females) groups are summarized in Tables 1 and 2 , respectively. Lifetime recreational drug use histories are summarized in Supplementary Tables 1 (AMP group) and 2 (THC group). All participants were healthy current or past occasional recreational cannabis users. Most were in their early twenties, selfidentified as "white," and reported light to moderate use of alcohol and other drugs. The groups did not differ on any of the demographic characteristics or on memory task performance under placebo conditions.
Emotional processing
Participants' subjective ratings were appropriate to the pictures' designated valence categories (AMP group, Table 3 ; THC group, Table 4), and positive and negative pictures were rated as significantly more arousing than neutral pictures, regardless of dose (p<0.001). Despite positive and negative pictures being equated on arousal according to normative ratings, participants in both the AMP and THC groups rated negative pictures as slightly, but significantly, more arousing than positive pictures in the placebo condition (p<0.001).
AMP AMP dose-dependently increased positivity and arousal ratings of the pictures during encoding. Accordingly, AMP (20 mg) significantly increased positivity (F 1, 23 05.83, p0 0.024, MSE00.3, η p 2 00.2) and arousal (F 1, 23 04.69, p0 0.041, MSE00.13, η p 2 00.16) ratings of the pictures overall, and these effects did not depend on picture valence (i.e., no dose×valence interactions). AMP did not alter negativity ratings.
THC The effects of THC on picture ratings have been previously reported elsewhere (Ballard et al. 2012a ). THC did not affect positivity ratings of the pictures overall. There was some indication that it increased arousal ratings, but only at the lower dose (quadratic dose-F 1, 23 06.56, p00.017, MSE00.46, η p 2 00.22 and linear dose-p00.33). This effect was mainly due to increased arousal ratings of neutral pictures (quadratic dose-F 1, 23 06.23, p 00.02, MSE00.72, η p 2 00.21), and positive pictures (quadratic dose-F 1, 23 04.03, p00.057, MSE00.7, η p 2 00.15). The lower 
Memory results
Raw hit rates and false alarm rates for pictures from each valence category are presented in Tables 5 (AMP group) and 6 (THC group). In general, hit rates were high and false alarm rates were low for all conditions, demonstrating good overall memory performance. There were no sex differences in memory performance under placebo conditions. Participants' memory did not vary depending on picture valence in the placebo conditions, and there were no significant differences between the two groups of participants in their memory for pictures of positive, neutral, or negative valence under placebo conditions. Although amygdale-hippocampal interactions can sometimes enhance memory for emotionally arousing information in a drug-free state (Kensinger 2004) , the high degree of conceptual overlap for emotional images also can increase memory confusions relative to unemotional images, thereby countering these otherwise beneficial effects of emotion (Gallo et al. 2009 ; see also Brainerd et al. 2008; D'Argembeau and Van der Linden 2004; Dougal and Rotello 2007; Howe 2007; Talmi et al. 2007) . For this reason, our focus was on each drug's potential effects on memory accuracy within a given emotional valence category, as opposed to the effects of emotional valence on memory accuracy within a given drug condition.
AMP As expected, AMP significantly improved memory performance overall (F 1, 23 06.27, p00.02, MSE032.13, η p 2 00.21), with both doses of AMP significantly increasing accuracy relative to placebo (t 23 s>3.01, p≤0.01). Although the dose×valence interaction was not significant, because of our a priori interest, we examined the drug's effect on memory for pictures from each valence category separately. These analyses indicated that, as shown in Fig. 1 Further analyses revealed that THC reduced hit rates for studied pictures (F 1, 23 08.61, p00.007, MSE029.26, η p 2 00.27) at both doses (t 2 3 s > 2.52, p < 0.006). Consistent with its effects on memory accuracy, THC primarily reduced hit rates for emotional pictures. The dose×valence interaction on hit rate narrowly missed significance (F 1, 23 04.15, p00.053, MSE022 .79, η p 2 0 0.15). Still, THC significantly reduced hit rates for positive pictures (F 1, 23 012.38, p00.002, MSE057.59, η p 2 00.35), and a similar trend was seen for negative pictures (F 1, 23 03.43, p00.077, MSE049.19, η p 2 00.13), whereas it did not robustly alter hit rates for neutral pictures. THC administration did not affect false alarm rates, and false alarms were very low across conditions. Subjective and physiologic effects of AMP and THC at encoding and relation to memory performance
The drugs' effects on select subjective drug response and mood measures and physiology at the time pictures were encoded are summarized in Tables 7 (AMP group) and 8 (THC group). Mean change from pre-capsule scores for all measures are detailed in Supplementary Tables 3 (AMP group) and 4 (THC group), and those for THC have been previously reported elsewhere (Ballard et al. 2012a ).
AMP AMP produced subjective and cardiovascular effects expected for a stimulant drug of abuse. Participants reported feeling the effects of only the higher dose of AMP (20 mg). Based on preference scores calculated as "dislike drug effects" scores subtracted from "like drug effects" scores, participants clearly preferred both doses of AMP to placebo, with ratings being roundly positive (range, −1.9 to 8.6 and −1.3 to 10, for the 10-and 20-mg dose, respectively). However, consistent with the finding that participants did not report feeling the 10-mg dose of AMP, only 12 out of the 25 study participants indicated a desire to take the 10-mg dose of AMP again, whereas 24 out of the 25 reported a desire to take the 20-mg dose again. AMP increased subjective ratings of stimulation (both doses) and reduced ratings of sedation (significant at 10 mg only). AMP also increased physiological arousal measures, including systolic and diastolic blood pressure, and heart rate. The majority of participants failed to correctly identify the 10-mg dose of AMP as a stimulant drug, but over half correctly identified the 20 mg dose of AMP as being stimulant-like (10 mg, 24 %; 20 mg, 64 %). Although AMP both enhanced memory and increased subjective drug effect and mood scale ratings and cardiovascular measures relative to placebo, exploratory correlational analyses did not suggest that AMP-induced memory changes were directly related to its subjective or cardiovascular effects across doses.
THC THC also produced expected subjective and cardiovascular effects. Participants reported feeling the effects of both doses of THC. However, they did not roundly prefer THC to placebo: There was wide inter-individual variability in preference for THC's effects (range, −4.0 to 4.7 and −7 to 6.2, for the 7.5-and 15-mg dose, respectively). Accordingly, Fig. 1 Effects of pre-encoding AMP on mean (±SEM) recognition accuracy. 1 0perfect discrimination, 0 0no discrimination (chance responding). *p<0.05; # p00.052 compared with placebo Fig. 2 Effects of pre-encoding THC on mean (±SEM) recognition accuracy. 1 0perfect discrimination; 0 0no discrimination (chance responding). *p<0.05 compared with placebo only 15 of the 25 study participants indicated a desire to take the 7.5-mg dose of THC again, and 11 of the 25 reported a desire to take the 15-mg dose again. THC increased ratings of both subjective stimulation and sedation at both doses, sometimes concomitantly. THC also increased physiological arousal measures. Just over half of the participants correctly identified THC as a marijuana-like drug (7.5 mg, 56 %; 15 mg, 52 %). Although THC both impaired memory and increased subjective drug effect and mood scale ratings and cardiovascular measures relative to the placebo condition, exploratory correlational analyses did not suggest that THCinduced memory changes were directly related to its subjective or cardiovascular effects across doses.
Discussion
This study investigated the acute effects of AMP and THC on emotional memory formation in human volunteers. We had two independent primary hypotheses. The first hypothesis was that both drugs would predominantly influence memory for emotional relative to neutral pictures. This hypothesis was supported: AMP enhanced, and THC impaired memory for both positive and negative pictures, but neither drug affected memory for neutral pictures. The second hypothesis was that both drugs would positively bias participants' memory of the emotional pictures. This hypothesis was not supported: neither AMP nor THC increased participants' tendency to endorse positive over negative studied or unstudied pictures as studied during memory testing. That AMP preferentially improved memory for emotional pictures is consistent with Hariri et al.'s (2002) report that AMP potentiates amygdalar reactivity to emotionally arousing images in humans. Together, these observations fit with data indicating that other experimental manipulations that similarly increase amygdalar reactivity (e.g., stress (van Marle et al. 2009 ) and cortisol (Henckens et al. 2012) ) also preferentially enhance emotional memory when administered prior to encoding in humans (Buchanan and Lovallo 2001; Payne et al. 2007) , but see also (Henckens et al. 2009; Henckens et al. 2012) . AMP increases DA and NE release in the amygdala (Rothman et al. 2001) , and it indirectly increases circulating levels of cortisol (White et al. 2006 )-all of which may enhance amygdalar reactivity in humans (Henckens et al. 2012; Onur et al. 2009; . Moreover in humans, both DA antagonists and β-adrenergic antagonists dampen amygdalar reactivity (Takahashi et al. 2005; van Stegeren et al. 2005) , and preencoding administration of either preferentially impairs emotional memory (Cahill et al. 1994; Gibbs et al. 2007; Mehta et al. 2005; van Stegeren et al. 1998 ). Thus, AMP may have enhanced emotional memory in the present study by increasing the perceived salience of emotional stimuli by the amygdala during encoding.
In addition to potentially enhancing emotional memory encoding, AMP may also have enhanced initial consolidation of emotional memories. Glucocorticoids, NE, and DA can further indirectly enhance hippocampal-dependent consolidation via actions on the amygdala (for a review, see McGaugh and Roozendaal 2009) , and glucocorticoids can also strengthen consolidation directly at the hippocampus (Micheau et al. 1984; Roozendaal and McGaugh 1997) . Consistent with the role of these hormones and transmitters in modulating arousal state, post-encoding stress, viewing of pleasant or aversive arousing videos, and cortisol all preferentially enhance emotional memory consolidation in healthy humans (Kuhlmann and Wolf 2006; Liu et al. 2008; Smeets et al. 2008) . Our finding with AMP, taken together with these other data, suggest emotional memory consolidation may be preferentially enhanced during periods of heightened arousal, and multiple neurochemical systems could play roles may mediating this effect. While we did not find evidence that AMP enhanced emotional memory most strongly in those participants who displayed the greatest AMP-induced increases in arousal, cortisol was not measured here. Therefore, AMP may have enhanced emotional memory encoding, early consolidation, or both. This enhancement may have been mediated by a potentiation of amygdalar facilitation of hippocampal binding resulting from increased release of glucocorticoids, NE, and DA.
That AMP preferentially enhanced emotional memory formation is important because it is the first demonstration of such a profile with a stimulant drug in humans. Previous studies have observed only a marginal emotional memory enhancement in humans with pre-encoding administration of yohimbine-an α-adrenergic antagonist that indirectly promotes NE release (O'Carroll et al. 1999; van Stegeren et al. 2010) . Furthermore, Brignell et al. (2007) found that pre-encoding administration of the amphetamine-like drug methylphenidate tended to improve neutral but not emotional memory. Precise reasons for the apparent discrepancies across these studies remain to be elucidated. They may be related to drug differences, but differences in the nature of the stimuli used may also be a significant factor. O 'Carroll et al. (1999) and Brignell et al. (2007) employed the emotional slide story task developed by Cahill and McGaugh (1995) . That task includes only 11 stimuli (four negatively valenced arousing slides buffered by seven neutral slides; positively valenced emotional material is not included). Because the emotional and neutral images are presented as part of a single story, this may limit the task's ability to differentiate the effects of drugs on emotional events from neutral events. Although van Stegeren et al. (2010) employed IAPS pictures in their study, they too included only those with neutral and negative valence. In the present study, we employed 20 positively valenced and 20 negatively valenced emotionally arousing images along with 20 neutrally valenced, lowarousal images spanning a range of topics. This picture task allowed us to more clearly differentiate the effects of drugs on the different kinds of emotional materials with varying content, thereby eliciting a broader range of emotional and cognitive associations. Also importantly contrasting with AMP, yohimbine did not potentiate amygdalar responses to emotional images during encoding in van Stegeren et al.'s (2010) study-consistent with the drug's inability to enhance emotional memory. Future studies employing functional neuroimaging techniques, wider dose ranges of these and other stimulant drugs, and memory tasks with a wider range of emotional stimuli will shed more light on these potential issues.
That THC preferentially impaired emotional memory is also consistent with its capacity to dampen amygdalar reactivity to emotionally arousing images in humans (Bhattacharyya et al. 2010; Phan et al. 2008) . Together, these observations fit with data indicating that other drugs that similarly dampen amygdala reactivity, including the addictive drugs alcohol (Gilman et al. 2008 ) and benzodiazepines (Del-Ben et al. 2010; Paulus et al. 2005) , also preferentially impair emotional memory when administered prior to encoding in humans (Buchanan et al. 2003; Knowles and Duka 2004) . As was the case in the current study, those other memory studies employed IAPS pictures of varying valence. Type-1 cannabinoid receptors densely populate the amygdala (Katona et al. 2001; Mackie 2005) , and their activation can inhibit excitatory input to this area of the brain (Azad et al. 2003) . Still, THC also has indirect effects on multiple hormonal and neurotransmitter systems that could have contributed to the observed performance effects (e.g., reduced DA and NE release in the amygdala (Szabo and Schlicker 2005) and increased cortisol release (Ranganathan et al. 2009)) . Therefore, while the precise neurochemical mechanisms underlying the effects of THC on emotional memory remain to be resolved, it seems likely THC may have reduced the perceived salience of emotional stimuli by the amygdala during encoding.
To the extent that THC induced feelings of sedation, our finding that it preferentially impaired emotional memory formation is also broadly consistent with research showing listening to relaxing music during or immediately after encoding preferentially impairs emotional memory in healthy humans (Liu et al. 2008) . Together, these data fit with the idea that emotional memory consolidation typically varies directly as a function of arousal state. Still, as with AMP, there was no evidence that the THC-induced emotional memory impairment was directly related to its sedative effects in this sample. Notably too, THC also increased subjective stimulation in some individuals and it increased physiological arousal-these effects were also not directly related to emotional memory changes. Evidence that cannabinoid agonists often impair retention of motivated conditioned behaviors in rodents (for reviews, see Akirav 2011; McLaughlin and Gobbi 2012) suggests that THC may have also impaired emotional memory consolidation in the present study, but there are presently few data regarding the effects of THC on memory consolidation in humans.
Contrary to our hypothesis that AMP and THC would positively bias memory, neither drug increased participants' tendency to remember positive pictures over negative pictures, even among those who most enjoyed the drugs' effects. We postulated that addictive drugs' reinforcing properties might derive in part from their tendency to induce a positive memory bias for drug-related events or experiences. This hypothesis was based on literature indicating that events are more likely to be remembered if their valence matches with the individual's mood state at the time they are perceived (for a review, see Eich 2001) . Still, the present data fit broadly with evidence suggesting that neither alcohol (Knowles and Duka 2004) nor benzodiazepines (Buchanan et al. 2003) appear to bias memory in favor of positive over negative stimuli viewed under the influence. Thus, while users' memory of prior positive drug experiences may drive subsequent drug taking, despite their euphorigenic properties addictive drugs do not seem to positively bias memory for the events experienced while under the influence.
Both AMP and THC affected participants' subjective ratings of the pictures during encoding, although these effects were not obviously related to the drugs' effects on memory. Replicating our previous finding (Wardle and de Wit 2012) , participants rated all pictures as more arousing and positive after AMP, regardless of valence. On the other hand, AMP preferentially enhanced memory for emotional pictures. After THC (7.5 mg), participants rated positive pictures as more arousing, while the drug dosedependently impaired memory for positive pictures. Participants also rated neutral pictures as more arousing after this dose of THC, but THC did not affect memory for neutral pictures. These findings are intriguing because they suggest that drugs' effects on emotional memory are not solely due to their effects on users' subjective evaluation of stimulus arousal during encoding.
The present study has several strengths, including the use of two doses of two pharmacologically distinct addictive drugs, a double-blind cross-over design with placebo controls, and memory testing occurred under drug-free conditions allowing us to isolate the effects of the drugs on memory formation (i.e., encoding and initial consolidation) from their potential effects on retrieval. It is important to point out, though, that it is possible that these findings would not generalize to higher doses (Baldi and Bucherelli 2005; Husain and Mehta 2011) , related drugs, or other routes of administration (Wachtel et al. 2002) . With respect to THC, it also is possible that whole plant cannabis, which contains other chemical compounds in addition to THC, would produce different effects (Zuardi et al. 1982 , but see Ilan et al. 2005; Karschner et al. 2011) . Furthermore, that studied pictures were discriminated with high accuracy under placebo conditions could have limited our ability to detect more robust memory changes. As such, studies including longer retention intervals, free recall memory assessments, and confidence ratings may be even more sensitive to the drug effects found here. Perhaps most importantly, it remains to be determined whether the drug effects observed here generalize to real-life situations (e.g., personally relevant emotional events, stressful conditions) and other populations (e.g., drug-naïve individuals, regular users (D'Souza et al. 2008) , patients with psychiatric disorders). These considerations suggest several interesting directions for future research.
In conclusion, our results add to a small but growing literature indicating that several addictive drugs have particularly strong effects on memory for emotional events in humans. We propose that these emotional memory effects are due to drug-induced changes in the functioning of brain regions involved in processing and storing emotional information, such as the amygdala. Future drug studies employing functional neuroimaging techniques could provide additional tests of this hypothesis. Finally, the results of the present study provide further evidence addictive drugs are not likely to positively bias users' subsequent memory of emotional events experienced under the influence-even among individuals who most enjoy their effects. Nevertheless, it remains a possibility that certain addictive drugs' memory effects may influence their appeal to certain users, or in certain situations.
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